By Jason Peterson, RPh, Director of Clinical Strategy at Navion
For decades, prescribing medication has followed a frustratingly familiar rhythm: try a drug, wait to see what happens, adjust the dose, switch therapies, repeat. It’s a process that works well enough for some patients and badly for others.
For those in the second group, “badly” can mean months of side effects, incomplete relief, avoidable risk and costs that quietly pile up. And here’s the thing: none of it is necessarily anyone’s fault. A medication that works for one person can fail another not because the diagnosis is wrong or the doctor is careless, but because human biology simply isn’t uniform.
That’s the promise — and the challenge — of pharmacogenomics.
What Is Pharmacogenomics (PGx) and Why Does It Matter for Employers?
Pharmacogenomics, or PGx, studies how a person’s genetic variation affects how they respond to medication. It can help identify whether a patient might metabolize a drug more slowly, more quickly, or differently than expected, which can meaningfully affect whether a medication is safe, effective, or correctly dosed.
For employers and health plans, this isn’t about finding a perfect drug for every member. PGx can’t do that. The realistic opportunity is narrower: reducing avoidable prescribing inefficiency where the gene-drug relationship is well understood and results are connected to a real prescribing decision.
PGx is increasingly discussed as though the test itself is the solution. It isn’t. A genetic result doesn’t interpret itself. Without that interpretation layer, PGx becomes just another report sitting outside the flow of care, impressive-looking, largely ignored.
Where Pharmacogenomic Testing Is Delivering Real Clinical Value
The strongest adoption is happening where the evidence is established and the consequences of getting medication wrong can be serious: behavioral health, cardiology, pain management, anticoagulation and oncology.
In behavioral health, patients often cycle through several medications before landing on something effective and tolerable. PGx can narrow the field earlier, flagging medications that may be less suitable based on how a patient metabolizes certain drugs. Fewer failed trials means less suffering, less cost and faster stabilization.
In cardiology, genetic variation can affect how well the body responds to drugs like clopidogrel. In anticoagulation, genetic variation can contribute to dose variability with warfarin, potentially increasing the risk of bleeding if dosing is not carefully managed. In pain management, certain genetic profiles change how patients respond to codeine or tramadol, which can influence both pain relief and toxicity risk. In oncology, PGx can flag patients at higher risk of severe toxicity from specific therapies.
These aren’t theoretical scenarios. They’re exactly the situations where genetics stops being interesting and starts being useful: when the drug, the patient and the decision point all line up.
Why Most Employer PGx Programs Don’t Change Prescribing Behavior
Here’s what the PGx conversation tends to gloss over: most employers aren’t actually running PGx programs. They’re talking about them. Vendors are pitching them. And occasionally a forward-thinking HR team adds one to the benefits lineup and quietly discovers that offering a test and changing prescribing behavior are two very different things.
The implementation gap between “we have a PGx benefit” and “that benefit measurably changed a prescribing decision” is real, wide and rarely discussed in the sales cycle.
The intervention isn’t the test. It’s the combination of testing, interpretation, workflow integration and clinician action. Those elements have to work together, because a genetic result that lives outside the prescribing moment, delivered in language a busy physician isn’t trained to act on, doesn’t change care no matter how scientifically sound it is.
The most important question a benefit consultant can ask a PGx vendor isn’t “what genes do you test?” It’s “what happens after the result?” Ideally, results are connected as close to the prescribing or dispensing moment as possible, so the clinical insight reaches the decision point before the medication becomes another failed trial or avoidable adverse event.
What a High-Performing Employer PGx Program Actually Looks Like
A responsible PGx program is targeted, clinically supported and operationally integrated. It starts with smart member identification, using medical and pharmacy data to find people most likely to benefit: high medication utilizers, members with treatment failures, or exposure to drug classes with strong PGx evidence.
From there, the program depends on clinical support. Results need to reach prescribers in a format they can actually use: concise, clinically contextualized, and timed to the prescribing decision. Pharmacists play a critical role here, bridging the gap between a lab finding and a medication change that neither the member nor the prescriber should have to navigate alone.
And employers should insist on accountability. Can the vendor answer basic questions? Who was tested, what did the results show, were medication changes made, and did adverse events or ineffective therapy cycles actually decline? If a vendor can’t answer those questions clearly, the program probably hasn’t moved beyond the test.
Can Pharmacogenomics Lower Pharmacy Costs for Self-Insured Employers?
The economic case is real but not automatic. The most credible cost pathway is indirect: if PGx reduces poorly matched medications, adverse drug reactions and repeated medication switches, it can lower waste and downstream utilization. The strongest evidence clusters around behavioral health, cardiovascular therapy and certain oncology treatments.
There’s growing interest in applying PGx to GLP-1 therapies, where variation in response and tolerability carries significant financial implications. When considering PGx in this category, employers should evaluate the opportunity around specific, defensible use cases, not broad promises.
The Bottom Line on PGx for Benefit Consultants and HR Leaders
Pharmacogenomics doesn’t end trial-and-error medicine. But in the right setting, with the right clinical support, it can reduce the guesswork that leads to failed therapies, avoidable side effects and wasted pharmacy spend.
For benefit consultants and employers, the real question isn’t whether PGx is promising. It’s whether the program is built to make that promise actionable.
The test may reveal the insight. Everything after the test determines whether that insight changes care.
Editor’s Note: This article was developed with insights contributed by clinicians at Blue Genes and Payer Matrix. Navion maintains an agnostic perspective on pharmacogenomics vendors and solutions.
